Mallinckrodt Pharmaceuticals Generics has entered into a strategic alliance with Zydus Cadila's US subsidiary, Zydus Pharmaceuticals Inc. The agreement calls for Mallinckrodt Pharmaceuticals Generics to market and sell products under a shared Mallinckrodt-Zypharma label. The products will be developed and registered by Zydus Pharmaceuticals and will be manufactured by Zydus Cadila at its US FDA-approved manufacturing plant in Ahmedabad, India.
By melding Mallinckrodt's marketing and distribution networks with Zydus Cadila's product development and manufacturing success, Mallinckrodt expands its product portfolio and pipeline.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs